Ac-DL-Leu-OH - CAS 99-15-0
Catalog number: 99-15-0
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C8H15NO3
Molecular Weight:
173.21
COA:
Inquire
Targets:
Others
Description:
Acetylleucine is a drug mianly used to treat the vertigo.It has been listed.
Purity:
>98 %
Appearance:
Solid powder
Synonyms:
Acetylleucine;N-Acetyl-DL-leucine;DL-Leucine,N-acetyl-;Acetyl-DL-leucine;Tanganil;2-Acetamido-4-methylpentanoic acid
Solubility:
10 mM in DMSO
Storage:
-20°C Freezer
MSDS:
Inquire
Application:
Acetylleucine is used to treat the vertigo.
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Kilogram to ton
Boiling Point:
369.7°Cat760mmHg
Melting Point:
369.7±25.0 °C | Condition: Press: 760 Torr
Density:
1.069±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
InChIKey:
WXNXCEHXYPACJF-UHFFFAOYSA-N
InChI:
InChI=1S/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12)
Canonical SMILES:
CC(C)CC(C(=O)O)NC(=O)C
Current Developer:
Acetylleucine has been listed.
1.[Drug therapy of vertigo].
Rascol O;Montastruc JL Rev Prat. 1994 Feb 1;44(3):354-60.
Drug treatment of vertigo is symptomatic. Highly varied classes of drugs are used, and their mechanisms of action are poorly known. The use of these drugs is empiric as they have been insufficiently evaluated. "Emergency" treatment of acute rotatory paroxysmal vertigo includes acetyl-dl-leucine (of unknown mechanism of action), vestibuloplegic drugs (anticholinergic drugs, H1 antihistamines and calcium antagonists), and dopaminergic antagonists (for their antiemetic properties). The length of such treatment should be short so as not to compromise spontaneous vestibular compensation. In case of recurrent or chronic vertigo, in order to avoid unnecessary prescription of antivertigo drugs, the physician must first eliminate non-vestibular vertigo (such as lipothymia, hypoglycemia or phobic manifestations), benign paroxysmal positional vertigo (which requires physical therapy) and tumours (such as acoustic neurinome, requiring surgery). To treat Ménière's disease, histaminergics and calcium antagonists are used, as well as drugs that are considered to diminish the pressure of the endolymphatic liquid (diuretics, acetazolamide, hyperosmotic substances). Their superiority to placebo has not been convincingly demonstrated.
2.N-acetyl-L-leucine accelerates vestibular compensation after unilateral labyrinthectomy by action in the cerebellum and thalamus.
Günther L;Beck R;Xiong G;Potschka H;Jahn K;Bartenstein P;Brandt T;Dutia M;Dieterich M;Strupp M;la Fougère C;Zwergal A PLoS One. 2015 Mar 24;10(3):e0120891. doi: 10.1371/journal.pone.0120891. eCollection 2015.
An acute unilateral vestibular lesion leads to a vestibular tone imbalance with nystagmus, head roll tilt and postural imbalance. These deficits gradually decrease over days to weeks due to central vestibular compensation (VC). This study investigated the effects of i.v. N-acetyl-DL-leucine, N-acetyl-L-leucine and N-acetyl-D-leucine on VC using behavioural testing and serial [18F]-Fluoro-desoxyglucose ([18F]-FDG)-μPET in a rat model of unilateral chemical labyrinthectomy (UL). Vestibular behavioural testing included measurements of nystagmus, head roll tilt and postural imbalance as well as sequential whole-brain [18F]-FDG-μPET was done before and on days 1,3,7 and 15 after UL. A significant reduction of postural imbalance scores was identified on day 7 in the N-acetyl-DL-leucine (p < 0.03) and the N-acetyl-L-leucine groups (p < 0.01), compared to the sham treatment group, but not in the N-acetyl-D-leucine group (comparison for applied dose of 24 mg i.v. per rat, equivalent to 60 mg/kg body weight, in each group). The course of postural compensation in the DL- and L-group was accelerated by about 6 days relative to controls. The effect of N-acetyl-L-leucine on postural compensation depended on the dose: in contrast to 60 mg/kg, doses of 15 mg/kg and 3.
3.[Pharmacotherapy of Vestibular Disorders, Nystagmus and Cerebellar Disorders].
Feil K;Böttcher N;Kremmyda O;Muth C;Teufel J;Zwergal A;Brandt T;Strupp M Fortschr Neurol Psychiatr. 2015 Sep;83(9):490-8. doi: 10.1055/s-0035-1553667. Epub 2015 Sep 30.
There are currently different groups of drugs for the pharmacotherapy of vertigo, nystagmus and cerebellar disorders: antiemetics; anti-inflammatories, antimenieres, and antimigraineous medications and antidepressants, anticonvulsants, aminopyridines as well as acetyl-DL-leucine. In acute unilateral vestibulopathy, corticosteroids improve the recovery of peripheral vestibular function, but currently there is not sufficient evidence for a general recommendation. There is insufficient evidence to support the view that 16 mg t. i. d. or 48 mg t. i. d. betahistine has an effect in Menière's disease. Therefore, higher dosages are recommended. In animal studies, it was shown that betahistine increases cochlear blood flow. In vestibular paroxysmia, oxcarbazepine was effective (one randomized controlled trial (RCT)). Aminopyridines are recommended for the treatment of downbeat nystagmus (two RCTs) and episodic ataxia type 2 (EA2, one RCT). There has been no RCT on the efficacy of beta-blockers or topiramate but one RCT on flunarizine in vestibular migraine. Based on clinical experience, a treatment analogous to that for migraine without aura can be recommended. Acetyl-DL-leucine improved cerebellar ataxia (two observational studies); it also accelerated central compensation in an animal model of acute unilateral lesion, but RCTs were negative.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 89-25-8 Edaravone

Edaravone
(CAS: 89-25-8)

Edaravone is a novel potent free radical scavenger that reduces reactive oxygen species, inhibites apoptosis, and blocks nonenzymatic peroxidation and lipoxygen...

Amidantel hydrochloride
(CAS: 69884-15-7)

Amidantel is a potent anthelminthic agent.

CAS 3734-33-6 Denatonium benzoate

Denatonium benzoate
(CAS: 3734-33-6)

Denatonium benzoate is a stimulant of the bitter taste receptors used as aversive agents (bitterants) to prevent inappropriate ingestion.

Remeglurant
(CAS: 1309783-00-3)

Remeglurant is a selective Metabotropic glutamate receptor 5 antagonist originated by Merz Pharmaceuticals. Phase-I for Drug-induced dyskinesia in USA was on-go...

CAS 82186-77-4 Benflumetol

Benflumetol
(CAS: 82186-77-4)

Benflumetol, also known as HSDB 7210, is an antimalarial drug used to treat acute uncomplicated malaria. It is used in combination with Artemether for improved ...

BMS-188494
(CAS: 191866-32-7)

BMS-188494 is the prodrug of BMS-187745, a squalene synthase inhibitor used as an anticholesterol drug.

LBM-415
(CAS: 478913-91-6)

LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, was tested by reference methods against 2 collections of pathogenic Neisseria being developed for c...

CAS 122018-58-0 PLP(139-151)

PLP(139-151)
(CAS: 122018-58-0)

PLP(139-151), a synthetic myelin proteolipid protein (PLP) fragment, induces experimental autoimmune encephalomyelitis (EAE).

Chemical Structure

CAS 99-15-0 Ac-DL-Leu-OH

Quick Inquiry

Verification code

Featured Items